Text Size
25 studies found for:    Open Studies | "Measles"

Modify this search | How to Use Search Results

Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Measles" (25 records)
Need help? See Downloading Content for Analysis
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Unknown † Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   Measles
Intervention: Biological: attenuated measles vaccine
2 Recruiting Additional Measles Vaccine at 4 Months of Age
Condition: Measles Infection
Intervention: Biological: Measles vaccine
3 Not yet recruiting Immunity to Measles Virus in the Thai Population Age 18-30 Years and Predictive Factors
Condition: Measles
Intervention:
4 Not yet recruiting Induction of Immunity Against Measles in Pediatric Liver Transplant Recipients
Condition: Measles
Intervention: Biological: MMR vaccination
5 Recruiting Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
Conditions: Measles;   Mumps;   Rubella
Intervention: Biological: MMR Vaccine
6 Not yet recruiting Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines
Conditions: Mumps;   Rubella;   Measles;   Varicella
Interventions: Biological: Priorix-Tetra™;   Other: Safety data collection
7 Recruiting Trial of Additional Measles Vaccine to Reduce Child Mortality
Condition: Measles Vaccine
Intervention: Biological: Early measles vaccine
8 Not yet recruiting Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso.
Condition: Measles Vaccine
Intervention: Biological: Early measles vaccine
9 Recruiting Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: Priorix®;   Biological: Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine (also known as M-M-R Vax Pro™);   Biological: Kinrix®;   Biological: Varivax®
10 Unknown † Ontogeny of Measles Immunity in Infants
Condition: Measles
Interventions: Biological: Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous);   Biological: MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)
11 Recruiting Coadministration of Measles-rubella and Rotavirus Vaccines
Conditions: Measles Antibody Seroconversion;   Rubella Antibody Seroconversion;   Rotavirus GMT;   Rotavirus IgA Seropositivity
Interventions: Biological: Rotarix vaccine;   Biological: measles-rubella vaccine
12 Recruiting A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices
Condition: Prophylaxis for the Measles Infection
Interventions: Biological: Dry Powdered Measles Vaccine;   Biological: Licensed Subcutaneous Measles Vaccine
13 Recruiting Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life
Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Bilogicals measles, mumps and rubella vaccine live (GSK 209762).;   Biological: Merck & Co., Inc.'s M-M-R®II, combined measles-mumps-rubella virus vaccine live.;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
14 Recruiting Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children
Conditions: Varicella;   Rubella;   Measles;   Mumps
Interventions: Biological: Priorix Tetra;   Biological: Meningitec
15 Unknown † The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants
Conditions: Immunity;   Measles;   Mumps;   Rubella
Interventions: Dietary Supplement: Probiotics (L.acidophilus and B.lactis);   Dietary Supplement: Cornflor
16 Recruiting Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age
Condition: Measles, Mumps and Rubella Diseases
Interventions: Biological: GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762).;   Biological: Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine.;   Biological: Varivax® (Merck & Co., Inc.);   Biological: Havrix®;   Biological: Prevnar 13® (Pfizer Inc.)
17 Recruiting Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
Conditions: Recurrent Malignant Mesothelioma;   Stage IA Malignant Mesothelioma;   Stage IB Malignant Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter;   Other: laboratory biomarker analysis;   Procedure: single photon emission computed tomography;   Procedure: computed tomography
18 Recruiting The Effect on Overall Mortality of a National Policy of Limiting Measles Vaccination to Children Below 12 Months of Age
Conditions: Mortality;   Vaccines
Intervention: Biological: Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine
19 Recruiting Recombinant Measles Virus Vaccine Therapy and Oncolytic Virus Therapy in Treating Patients With Progressive, Recurrent, or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Primary Peritoneal Cavity Cancer
Interventions: Biological: carcinoembryonic antigen-expressing measles virus;   Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis
20 Recruiting Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: carcinoembryonic antigen-expressing measles virus;   Genetic: fluorescence in situ hybridization;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: needle biopsy;   Procedure: neoadjuvant therapy
To Top

Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results
† Indicates status has not been verified in more than two years